Cargando…

Descriptive Analysis of First-Line Non-Small Cell Lung Cancer Treatment with Pembrolizumab in Tumors Expressing PD-L1 ≥ 50% in Patients Treated in Quebec’s University Teaching Hospitals (DALP-First Study)

Since July 2017, pembrolizumab has been approved as a first-line treatment of metastatic non-small cell lung cancer (NSCLC) in patients with a PD-L1 score ≥ 50% in Quebec. Study objectives were to describe and assess the real-world use of pembrolizumab; report progression-free survival (PFS), overal...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bérard, Ghislain, Guévremont, Chantal, Marcotte, Nathalie, Schroeder, Coleen, Bouchard, Nicole, Rajan, Raghu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10047395/ https://www.ncbi.nlm.nih.gov/pubmed/36975460 http://dx.doi.org/10.3390/curroncol30030247

Ejemplares similares

Genetic Dissection of Sympatric Populations of Brown Planthopper, Nilaparvata lugens (Stål), Using DALP-PCR Molecular Markers
por: Latif, M. A., et al.
Publicado: (2012)

Outcomes to first-line pembrolizumab in patients with PD-L1-high (≥50%) non–small cell lung cancer and a poor performance status
por: Alessi, Joao V, et al.
Publicado: (2020)

Tumor metabolic volume by (18)F-FDG-PET as a prognostic predictor of first-line pembrolizumab for NSCLC patients with PD-L1 ≥ 50%
por: Yamaguchi, Ou, et al.
Publicado: (2020)

Real-World Outcomes of Stage IV NSCLC with PD-L1 ≥ 50% Treated with First-Line Pembrolizumab: Uptake of Second-Line Systemic Therapy
por: Rittberg, Rebekah, et al.
Publicado: (2023)

First‐line pembrolizumab for non–small cell lung cancer patients with PD‐L1 ≥50% in a multicenter real‐life cohort: The PEMBREIZH study
por: Amrane, Karim, et al.
Publicado: (2020)

Real-World Time on Treatment with First-Line Pembrolizumab Monotherapy for Advanced NSCLC with PD-L1 Expression ≥ 50%: 3-Year Follow-Up Data
por: Velcheti, Vamsidhar, et al.
Publicado: (2022)

New Curculionoidea (Coleoptera) records for Quebec, Canada
por: de Tonnancour, Pierre, et al.
Publicado: (2017)

Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: a multicenter study with external validation
por: Cortellini, Alessio, et al.
Publicado: (2020)

Real-world multicentre cohort of first-line pembrolizumab alone or in combination with platinum-based chemotherapy in non-small cell lung cancer PD-L1 ≥ 50%
por: Pons-Tostivint, E., et al.
Publicado: (2023)

Prediction of patients with a tumor proportion score > 50% who do not respond to first-line monotherapy with pembrolizumab
por: Morita, Mitsunori, et al.
Publicado: (2020)

Immunotherapy “Shock” a case series of PD-L1 100% and pembrolizumab first-line treatment
por: Zarogoulidis, Paul, et al.
Publicado: (2017)

First-line treatment for patients with advanced non-small cell lung carcinoma and high PD-L1 expression: pembrolizumab or pembrolizumab plus chemotherapy
por: Zhou, Yixin, et al.
Publicado: (2019)

Pre‐existing interstitial lung disease does not affect prognosis in non‐small cell lung cancer patients with PD‐L1 expression ≥50% on first‐line pembrolizumab
por: Yamaguchi, Ou, et al.
Publicado: (2020)

PEOPLE (NTC03447678), a phase II trial to test pembrolizumab as first-line treatment in patients with advanced NSCLC with PD-L1 <50%: a multiomics analysis
por: Lo Russo, Giuseppe, et al.
Publicado: (2023)

Correction to: Real-world multicentre cohort of first-line pembrolizumab alone or in combination with platinum-based chemotherapy in non-small cell lung cancer PD-L1 ≥ 50%
por: Pons-Tostivint, E., et al.
Publicado: (2023)

Cost-Effectiveness of Pembrolizumab Plus Chemotherapy Versus Pembrolizumab Monotherapy in Metastatic Non-Squamous and Squamous NSCLC Patients With PD-L1 Expression ≥ 50%
por: Liu, Qiao, et al.
Publicado: (2022)

Pembrolizumab: First in Class for Treatment of Metastatic Melanoma
por: Barnhart, Carrie
Publicado: (2015)

Diagnostics of CAPS in Quebec thanks to teaching program
por: Chetaille, A-L, et al.
Publicado: (2015)

Cost‐effectiveness analysis of pembrolizumab plus chemotherapy with PD‐L1 test for the first‐line treatment of NSCLC
por: Wan, Ning, et al.
Publicado: (2020)

Pembrolizumab Alone or Combined With Chemotherapy in Advanced NSCLC With PD-L1 ≥50%: Results of a Retrospective Study
por: Chen, Ya, et al.
Publicado: (2021)

Pembrolizumab as first-line treatment for metastatic uveal melanoma
por: Rossi, Ernesto, et al.
Publicado: (2019)

Good Response of Advanced Thymic Carcinoma with Low PD-L1 Expression to Chemotherapy plus Pembrolizumab as First-Line Therapy and to Pembrolizumab as Maintenance Therapy: A Case Report
por: Nishii, Yoichi, et al.
Publicado: (2022)

The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer
por: Banna, G.L., et al.
Publicado: (2021)

KRAS(G12C)/TP53 co-mutations identify long-term responders to first line palliative treatment with pembrolizumab monotherapy in PD-L1 high (≥50%) lung adenocarcinoma
por: Frost, Nikolaj, et al.
Publicado: (2021)

The Quebec Pregnancy Cohort – Prevalence of Medication Use during Gestation and Pregnancy Outcomes
por: Bérard, Anick, et al.
Publicado: (2014)

An Exploratory Mixed-method Descriptive Analysis of Youth Coping during the First Wave of the COVID-19 Pandemic in Quebec
por: Hébert, Martine, et al.
Publicado: (2022)

Current status of first‐line treatment with pembrolizumab for non–small‐cell lung cancer with high PD‐L1 expression
por: Ikezawa, Yasuyuki, et al.
Publicado: (2022)

Le burlesque au Québec : un divertissement populaire
por: Hébert, Chantal
Publicado: (1981)

Multifocal choroiditis as the first sign of systemic sarcoidosis associated with pembrolizumab
por: Lise, Qu-Knafo, et al.
Publicado: (2016)

Pembrolizumab-related renal toxicities: diagnosis first, treatment later
por: Sprangers, Ben
Publicado: (2018)

Ambio - The first 50 years
por: Söderström, Bo
Publicado: (2020)

Community Remoteness, Perinatal Outcomes and Infant Mortality among First Nations in Quebec
por: Wassimi, Spogmai, et al.
Publicado: (2010)

Preterm birth in the Inuit and First Nations populations of Québec, Canada, 1981–2008
por: Auger, Nathalie, et al.
Publicado: (2012)

Successful Response of Pembrolizumab Rechallenge after Radiotherapy for a Patient with Bladder Cancer of Nonresponse of Pembrolizumab First Challenge
por: Ikeda, Taro, et al.
Publicado: (2021)

Cost Effectiveness of PD-L1-Based Test-and-Treat Strategy with Pembrolizumab as the First-Line Treatment for Metastatic NSCLC in Hong Kong
por: Loong, Herbert H., et al.
Publicado: (2019)

Descriptive study of interprofessional collaboration between physicians and osteopaths for the pediatric population in Quebec, Canada
por: Morin, Chantal, et al.
Publicado: (2017)

EGFR or PD-L1 decision for first line therapy in a case series of EGFR positive and PD-L1 >50%
por: Zarogoulidis, Paul, et al.
Publicado: (2017)

Alternate Pembrolizumab Dosing Interval in Advanced NSCLC with PD-L1 TPS ≥ 50%: 3 Weekly Compared to 6 Weekly Dosing
por: Jones, Lauren, et al.
Publicado: (2022)

Counting the Dead: COVID-19 and Mortality in Quebec and British Columbia During the First Wave
por: Décarie, Yann, et al.
Publicado: (2021)

Community Treatment Orders use Among Persons With a First Episode of Psychosis in Quebec
por: Nguyen, Minh Thi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_2lia04oseg69gbd8uqq14c5ced